## WST: West Pharmaceutical Services, I - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%); PEG 3.43 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($256.28)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. West Pharmaceutical Services Keeps Quarterly Dividend at $0.22 a Share, Payable Feb. 4 to Shareholders of Record on Jan. 28**
- Source: marketscreener.com | 20251210T121229 | Somewhat-Bullish | Relevance: 99%
-  West Pharmaceutical Services, Inc. has announced that it will maintain its quarterly dividend at $0.22 per share. This dividend is payable on February 4 to shareholders who are on record as of January 28. The company is a specialist in manufacturing components and systems for injectable drugs.

**2. West Pharmaceutical Services declares quarterly dividend of $0.22 By Investing.com**
- Source: Investing.com Australia | 20251210T120008 | Bullish | Relevance: 98%
-  West Pharmaceutical Services, Inc. has declared a regular quarterly dividend of $0.22 per share, continuing its 53-year streak of dividend payments and 33 consecutive years of dividend increases. The dividend is payable on February 4, 2026, to shareholders of record as of January 28, 2026. This announcement follows several analyst updates with positive outlooks and increased price targets for the company.

**3. Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now**
- Source: TradingView | 20251211T130913 | Somewhat-Bullish | Relevance: 98%
-  West Pharmaceutical Services (WST) shows strong growth potential due to robust GLP-1 related demand and expansion, with its High-Value Product (HVP) components driving growth and a significant tailwind from Annex 1 regulatory requirements. Despite these positive indicators, the company faces challenges including contract manufacturing headwinds, timing variability in Annex 1 conversions, and profitability drags from delivery devices. Investors should consider these factors when evaluating WST's stock, which currently holds a Zacks Rank #3 (Hold).

**4. West Declares Quarterly Dividend**
- Source: PR Newswire | 20251210T110228 | Somewhat-Bullish | Relevance: 98%
-  West Pharmaceutical Services, Inc. (NYSE: WST) has declared a regular quarterly dividend of $0.22 per share on its common stock. This dividend is payable on February 4, 2026, to shareholders of record as of January 28, 2026. West is a global leader in innovative injectable drug administration solutions, generating $2.89 billion in net sales in fiscal year 2024.

**5. Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now**
- Source: Yahoo Finance Singapore | 20251211T130903 | Somewhat-Bullish | Relevance: 97%
-  West Pharmaceutical Services, Inc. (WST) is well-positioned for growth driven by strong demand for GLP-1 related products and strategic expansion plans. Despite concerns about pricing headwinds and tariff risks, the company demonstrates strong momentum in High-Value Product (HVP) components, expanding GLP-1 opportunities, and improving free cash flow. Key challenges include contract manufacturing headwinds, variability in Annex 1 implementation, and profitability issues within delivery devices.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $285 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.01M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.9% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Vanguard Group Inc: 13.5% (+4.2%)
- Blackrock Inc.: 9.0% (-2.3%)
- State Street Corpora: 4.5% (-1.9%)
- Bank Of New York Mel: 4.0% (-9.4%)
- Artisan Partners Lim: 3.9% (+22.2%)

### Key Risks

1. Valuation stretched: PEG 3.4x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.43 signals overvaluation risk, limited margin of safety. Forward P/E 35.0x stretched relative to 10% growth. Quality metrics strong (ROA 10%, margin 16%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.35). Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $19.6B |
| Beta | 1.17 |
| 52W Range | $187.43 - $348.90 |
| Short Interest | 3.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.43 |
| Forward P/E | 35.0 |
| Current P/E | 38.4 |
| YoY Growth | 9.6% |
| EPS Direction | RISING |

### Technicals

MRS_10 weakening modestly (-0.5% over 5 days). Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. MACD histogram bearish (-0.55), momentum weakening. RSI neutral at 50.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.14% (CS: 26) | Neutral |
| RSI_14 | 49.8 | Neutral |
| MACD Histogram | -0.55 | Bearish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 0.996x | Below |
| vs SMA200 | 1.135x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $272.54
- **Stop Loss:** $256.28 (6.0% risk)
- **Target:** $288.80 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 84
- **Position Value:** $22,893.36
- **Portfolio %:** 22.89%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-12 (Est: $1.83)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.71 | $1.96 | +14.5% |
| 2025Q2 | $1.54 | $1.84 | +19.7% |
| 2025Q1 | $1.26 | $1.45 | +15.3% |
| 2024Q4 | $1.73 | $1.82 | +5.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*